Contact: Mr. Lang13612820654

Smart Medical Devices Network News: Kossel, a pan-vascular interventional platform company, has resumed its M&A activities, completing two consecutive acquisitions of Shanghai-based enterprises within a few months.

Completed the strategic acquisition of Shanghai Baiquantong in early 2026, and recently announced the acquisition of Shanghai Xinzhi Medical., two successive acquisitions have respectively strengthened its core businesses in peripheral active ultrasound and coronary drug-coated balloons, continuously enhancing its comprehensive product portfolio spanning from imaging equipment to consumables.

In 2013, Kossel strategically targeted the therapeutic end throughOctoparms^®Vena cava filter, K-Rhino™ thrombus aspiration system, Tanghulu^®Tanghulu Ballproduct portfolio including balloons, establishing advantages in the treatment of venous diseases, arteriovenous thrombus removal, and vascular preparation. The core purpose of this acquisition of Baiquantong Medical is to strengthen the key diagnostic segment of "intravascular imaging."

Baiquantong Medical's Self-DevelopedK-VisionMax™ Jingbao™ disposable peripheral ultrasound diagnostic catheter and intravascular ultrasound diagnostic equipment are at the leading level in China,It can provide real-time 3D imaging of the vascular lumen, vessel wall, and surrounding structures. It demonstrates significant advantages in key performance parameters, clinical applicability, supply chain stability, and cost control, thereby effectively enhancing the precision of intraoperative decision-making and improving long-term patient outcomes. The deep integration of diagnostic and therapeutic toolchains will further accelerate the implementation of Kossel’s integrated precision diagnosis and treatment solutions.

Kossel’s current M&A is based on two core judgments:First, the market potential for functional balloons is clearly expanding; second, innovative rapamycin-coated balloon technology has reached the tipping point for large-scale clinical application.

In terms of market potential, the usage volume of drug-coated balloons has grown rapidly following centralized procurement. The concept of "intervention without implantation" is reshaping global standards for coronary diagnosis and treatment, with drug-coated balloons serving as the core vehicle for this transformation. Data indicates that the market size for general-purpose coronary balloons has declined after the implementation of centralized procurement.However, the market size for functional balloons, including scoring balloons, cutting balloons, non-compliant balloons with protrusions, and drug-coated balloons, has continued to grow.

By extending the time horizon and broadening industry perspectives, it becomes evident that this merger is not an isolated incident but another critical validation of Kossel’s dual-wheel drive strategy of “independent innovation + ecosystem integration.” This path of ecosystem integration, underpinned by long-termism, was foreshadowed as early as the initial stages of the company’s development.

Reviewing Kossel’s thirteen-year development journey, its growth trajectory is clearly discernible:

From early, focused breakthroughs in vena cava filters to the systematic establishment of a platform-based layout across four major segments—peripheral intervention, electrophysiology, coronary intervention, and core raw materials; from completing its first overseas acquisition by acquiring the Irish company Micell, thereby achieving global regulatory approvals and commercial deployment, to executing two successive domestic acquisitions—these represent key implementation steps in Kossel’s mid-to-long-term ecological strategy.

Two Sequential, Differentiated Acquisitions: One Bolstering Peripheral Imaging, the Other Coronary Consumables—Kossel’s Pan-Vascular Full Industry Chain Puzzle Becomes Increasingly Complete. Amid the Accelerating Consolidation in the Medical Device Industry, It Has Become Common Practice for Platform Enterprises to Fill Pipeline Gaps Through Mergers and Acquisitions, Suggesting That the Concentration of the Domestic Interventional Device Industry May Continue to Rise.

Editor-in-Chief's Direct Line

1

Corporate interviews, in-depth promotional coverage of products and technologies, industry report consulting, and submissions;

2

Contact: 13714842321 (WeChat)